KA
MRNA icon

Kintegral Advisory’s Moderna MRNA Stock Holding History

Kintegral Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,894
Closed -$85.3K – 234
2025
Q4 		$85.3K Buy
+2,894
New +$78.6K 0.01% 234
2025
Q3 		– Sell
-2,986
Closed -$82.4K – 237
2025
Q2 		$82.4K Sell
2,986
-5
-0.2% -$132 0.01% 237
2025
Q1 		$84.8K Sell
2,991
-11
-0.4% -$390 0.01% 238
2024
Q4 		$125K Sell
3,002
-139
-4% -$6.64K 0.01% 238
2024
Q3 		$210K Sell
3,141
-41
-1% -$3.76K 0.02% 238
2024
Q2 		$378K Buy
3,182
+49
+2% +$6.2K 0.04% 236
2024
Q1 		$334K Sell
3,133
-10
-0.3% -$1.01K 0.03% 247
2023
Q4 		$313K Buy
+3,143
New +$264K 0.03% 249

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kintegral Advisory's MRNA Position: Q1 2026 in Review

Kintegral Advisory sold out of Moderna (MRNA) in Q1 2026, closing a stake of 2,894 shares — an estimated $85.3K sold.

Kintegral Advisory first reported a position in MRNA in Q4 2023 and held it in 8 quarters. The position peaked at $378K in Q2 2024. 723 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Kintegral Advisory reported no remaining Moderna position as of Q1 2026 after selling out during the quarter.
  • Kintegral Advisory sold 2,894 Moderna shares in Q1 2026, an estimated $85.3K.
  • Kintegral Advisory first reported a position in Moderna in Q4 2023 and held it in 8 quarters.
  • Kintegral Advisory's Moderna position peaked at $378K in Q2 2024.
  • 723 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Kintegral Advisory's 13F filing for Q1 2026, filed 14 May 2026.